A clinical study of MK-6916 and placebo in healthy people (MK-6916-003)

2024-516878-30-00 Protocol MK-6916-003 Human pharmacology (Phase I) - Other Ended

Start 10 Dec 2024 · End 9 Apr 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol MK-6916-003

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 16
Countries 1
Sites 1

Acute and chronic Pain

Key facts

Sponsor
Merck Sharp & Dohme LLC
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
10 Dec 2024 → 9 Apr 2025
Decision date (initial)
2024-12-03
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-516878-30-00
WHO UTN
U1111-1311-2867

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Acute and chronic Pain

VersionLevelCodeTermSystem organ class
20.1 LLT 10066714 Acute pain 10018065
20.1 LLT 10049475 Chronic pain 10018065

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Merck Sharp & Dohme LLC

Sponsor organisation
Merck Sharp & Dohme LLC
Address
126 East Lincoln Avenue, P. O. Box 2000 P. O. Box 2000
City
Rahway
Postcode
07065-4607
Country
United States

Scientific contact point

Organisation
Merck Sharp & Dohme LLC
Contact name
Jonathan Kurz

Public contact point

Organisation
Merck Sharp & Dohme LLC
Contact name
Jonathan Kurz

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ended 16 1
Rest of world 0

Investigational sites

Belgium

1 site · Ended
UZ Leuven
Center for Clinical Pharmacology, Herestraat 49, 3000, Leuven

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2024-12-10 2025-04-08 2024-12-12 2025-03-26

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-10-21 Belgium Acceptable
2024-12-03
2024-12-03